Survodutide
SYNCHRONIZE™JP
Boehringer Ingelheim · Phase 3 · Completed · Enrollment 274
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Survodutide - 3.6 mg | n/r | n/r | n/r | n/r | n/r |
| Survodutide - 6.0 mg | n/r | n/r | n/r | n/r | n/r |
| Placebo group | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.